Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard and invested so many of our tax paid hours on creating. Moving in this direction would have devastating consequences for medical research, including the  Defense Health Research Programs at the Department of Defense (DoD) of which our own Prostate Cancer Research Program (PCRP) is a [...]

By | November 18th, 2016|advocacy, DOD, DOD PCRP, NIH, Research, Uncategorized|0 Comments

Prostate Cancer drugs cost more in the USA than in other countries.

The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group.  The average US wholesale price of Xtandi in 2015 was $88 per capsule.   That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. The higher the cost, the more likely that insurance companies will  require pre-authorization to cover the cost of the drug.  That means a man dealing with advanced stage disease is tasked with asking his doctor to spend uncompensated time fighting the insurance company for his [...]

U.S. Congress Passes Omnibus Funding with Significant Increases for Medical Research

We have some good news, the United States Congress has passed the Omnibus spending package.  The package will fund the U.S. Government through fiscal 2016.  We should take note that this bill includes a $2 billion increase for the National Institute of Health (NIH), a 5% increase for the National Cancer Institute (NCI) and the Food and Drug Administration (FDA).  The bill also includes funding for the Department of Defense Medical Research Program with an allocation of $80 million for the Prostate Cancer Research Program. My only disappointment is that the DOD PCRP (Prostate Cancer Research Program) didn't receive additional [...]

By | December 20th, 2015|advocacy, DOD PCRP, FDA, NCI, NIH, Politics of Cancer, Uncategorized, United States|0 Comments

US Government Begins to Crack Down on Clinical Trials Reporting

Yes, it is true, many clinical trial results are not published, especially negative results. This is even true for FDA approved drugs and treatments! Failing to publish, or actually hiding negative results and harmful side effects that occur in clinical trials is too common and jeopardizes each and everyone of us, including survivors of advanced prostate cancer. Under some new proposed legislation by the US National Institutes of Health (NIH) and the Food and Drug Administration (FDA) it would become harder in the United States to do this in the future. One of the proposals would require companies seeking the [...]

By | November 25th, 2014|Clinical Trials, Clinical Trials, FDA, General Information, NIH, Uncategorized|0 Comments
スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー